register

ESG

Johnson & Johnson sets high standards for health equity and social impact through local resource investment

Health Industry Hub | April 15, 2024 |

ESG: Deborah Guion, Head of Health Equity at Johnson & Johnson Australia and New Zealand, delved into the company’s dynamic journey towards prioritising health equity and social impact.

In this interview with Health Industry Hub, Ms Guion who heads up the role for J&J MedTech and J&J Innovative Medicine (previously Janssen) locally, highlighted several key factors driving the outcomes of the recently released ANZ Impact Report.

Ms Guion stressed the importance of senior leadership commitment in driving health equity and social impact, saying “Last year, our two managing directors, Sue Martin and Urs Voegeli took time to travel to Arnhem Land with me, and they sat and listened to community talk about the challenges they face.”

Shedding light on the initiatives with the most profound outcomes, she delved into Johnson & Johnson’s strategy for involving employees in social impact projects, emphasising the significance of cultivating a culture of shared responsibility.

When confronted with the inevitable challenges of driving social and community impact, Ms Guion acknowledged the complexities involved but emphasised the importance of persistence and adaptability.

Looking towards the future, Ms Guion highlighted the emerging trends in health equity and social impact within the industry. She emphasised the increasing integration of data-driven approaches, as well as the growing emphasis on partnerships and collective action to address pressing societal challenges.

“It is a great opportunity for knowledge sharing across the sector because ultimately, the community work that each of us are doing is for the greater benefit of humanity,” she stated.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.